How your com­pa­ny can fund the work at End­points News — and give your em­ploy­ees com­plete ac­cess to our con­tent

Last sum­mer we launched a prod­uct — En­ter­prise — that is es­sen­tial to the fu­ture of End­points News. Cor­po­rate cus­tomers can now di­rect­ly sup­port our fu­ture de­vel­op­ment through paid sub­scrip­tions, and get a list of ex­tra ben­e­fits and con­tent. If you’d like to sup­port the work, please con­sid­er do­ing so to­day. (We al­so have a prod­uct for in­di­vid­u­als called In­sid­er, which you can read about here.)

The news is this: We want to hit our sub­scrip­tion rev­enue goals now so we can ex­pand the team, bring­ing you even bet­ter re­port­ing soon­er rather than lat­er.  It’s just $1,000/year for your en­tire com­pa­ny no mat­ter the size — and you can see one of the ben­e­fits be­low. Every em­ploy­ee who sub­scribes to End­points News will be­gin to see this new spe­cial email head­er that demon­strates your com­pa­ny’s sup­port.

Spe­cial head­er em­ploy­ees would see with an En­ter­prise sub­scrip­tion


This isn’t a plea for do­na­tions. With a paid sub­scrip­tion, we’re pro­vid­ing you val­ue and new tools (more on that be­low) and in ex­change we’re charg­ing a price.

To do in­de­pen­dent jour­nal­ism root­ed in the style John and I have set out since we launched — 2 years, 3,700 ar­ti­cles and 500 dai­ly newslet­ters ago — here’s one ab­solute truth: Read­ers must di­rect­ly sup­port the busi­ness mod­el. And now your com­pa­ny can.

Give your em­ploy­ees full ac­cess to end­points news

Let’s say your com­pa­ny has 2,000 em­ploy­ees. Per­haps 500 of them vis­it our web­site and 50 of them are free email sub­scribers. For just $1,000/year, you can in­stant­ly up­grade all 50 to En­ter­prise — and then as long as your sub­scrip­tion is cur­rent, we’ll au­to­mat­i­cal­ly flag all new email sub­scribers from your cor­po­rate do­main and grant them full ac­cess to your firm’s En­ter­prise li­cense.

All of your em­ploy­ees who sub­scribe to End­points News will see the spe­cial head­er in their newslet­ter, re­mind­ing them of your com­pa­ny’s sup­port of in­de­pen­dent jour­nal­ism. We’ll send them all pre­mi­um End­points con­tent which is ex­clu­sive to paid sub­scribers on­ly. And there’s more. Your em­ploy­ees al­so get:

  • Print-to-PDF: The PDF but­ton above all our news ar­ti­cles will now work.
  • Cut-and-paste rights: Share our work legal­ly in full, with­out the URL, in­ter­nal­ly or with part­ners, in any dig­i­tal medi­um. A huge li­brary of news con­tent at their fin­ger­tips. With­out a sub­scrip­tion, just a fair-use, lim­it­ed amount is per­mis­si­ble.
  • Reprint rights: Go ahead and print our ma­te­r­i­al for busi­ness use, they’d have our full per­mis­sion.

And now:

    • Two Pre­mi­um Job List­ings: At End­points Ca­reers, we of­fer a way for cor­po­rate sub­scribers to get their open po­si­tions in front of our en­tire sub­scriber base. We’re of­fer­ing two free Pre­mi­um List­ings per year to each cor­po­rate cus­tomer. That is an $1,800 cost by it­self, which alone ex­ceeds the cost of a one year sub­scrip­tion.

Pay­wall ac­cess

Once you sub­scribe, here’s just a sam­ple of the con­tent every­one at your com­pa­ny will have ac­cess to:

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017


What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M


The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018


Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017


What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?


The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

… and much more to come


Now is the time to sup­port the work

To the hun­dreds of amaz­ing com­pa­nies and in­di­vid­u­als who’ve al­ready signed up, thank you — what we do isn’t pos­si­ble with­out you.

If you’ve been think­ing about it but have put it off, we to­tal­ly get it. But we need your help this month if we’re to hit the lofty to­tals that’ll al­low us to hire a top-class team and build new prod­ucts while main­tain­ing our in­de­pen­dence.

Get End­points En­ter­prise

We’ve de­signed a re­al­ly easy form that takes a cou­ple min­utes to fill out, and re­quires a cred­it card pay­ment at the end. With­in 24 hours, usu­al­ly much soon­er, you’ll get an email with a full PDF li­cense. You can see the en­tire terms and con­di­tions here. All of your em­ploy­ees can start en­joy­ing the ben­e­fits of a sub­scrip­tion im­me­di­ate­ly.

Need help? Now many com­pa­nies have com­pli­cat­ed billing process­es and pro­to­cols. You can chat with our team dur­ing busi­ness hours via our up­grade page or Read­er Cen­ter should you re­quire spe­cial as­sis­tance. To sign in, you can use a tra­di­tion­al pass­word or click a se­cure “mag­ic link” that we send to your email on file with us. You can al­so send an email to help@end­pointsnews.com.

We re­quire a cred­it card pay­ment but in lim­it­ed cir­cum­stances can in­voice your com­pa­ny if there is no al­ter­na­tive.

To be­gin your com­pa­ny’s paid sub­scrip­tion, click on the but­ton be­low.

Get End­points En­ter­prise

Once again, this is a cru­cial month for this com­pa­ny. You can di­rect­ly sup­port our fu­ture de­vel­op­ment, so we can build on the track we’ve laid so far. We’ll have more posts over the month on our pro­grams but we need your sup­port to­day. Thanks for be­ing part of the End­points News com­mu­ni­ty.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

San Diego cou­ple charged with steal­ing trade se­crets, open­ing Chi­nese biotech as DOJ crack­down con­tin­ues

A San Diego couple has been charged with stealing trade secrets from a US hospital and opening a business based off those secrets in China as the controversial industry-wide crackdown on alleged corporate espionage continues. On the same day, the Department of Justice announced they had arrested Beijing representative Zhongsan Liu for allegedly trying to obtain research visas for government recruiters.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire. Lundbeck

UP­DAT­ED: Deb­o­rah Dun­sire is pay­ing $2B for a chance to leap di­rect­ly in­to a block­buster show­down with a few of the world's biggest phar­ma gi­ants

A year after taking the reins as CEO of Lundbeck, Deborah Dunsire is making a bold bid to beef up the Danish biotech’s portfolio of drugs in what will likely be a direct leap into an intense rivalry with a group of giants now carving up a growing market for new migraine drugs.

Bright and early European time Monday morning the company announced that it will pay up to about $2 billion to buy Alder, a little biotech that is far along the path in developing a quarterly IV formulation of a CGRP drug aimed at cutting back the number of crippling migraines patients experience each month. In a followup call, Dunsire also noted that the company will likely need 200 to 250 reps for this marketing task on both sides of the Atlantic. And analysts were quick to note that the dealmaking at Lundbeck isn’t done, with another $2 billion to $3 billion available for more deals to beef up the pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Tower Bridge in London [Shutterstock]

#UK­BIO19: Join GSK’s Hal Bar­ron and a group of top biotech ex­ecs for our 2nd an­nu­al biotech sum­mit in Lon­don

Over the past 10 years I’ve made a point of getting to know the Golden Triangle and the special role the UK biopharma industry plays there in drug development. The concentration of world class research institutes, some of the most accomplished scientists I’ve ever seen at work and a rising tide of global investment cash leaves an impression that there’s much, much more to come as biotech hubs are birthed and nurtured.

UP­DAT­ED: Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

One of Biogen’s attempts to branch out has flopped as the biotech scraps a mid-stage program for idiopathic pulmonary fibrosis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Warts for the win: Aclar­is' lead drug clears piv­otal study

Aclaris Therapeutics has found a way to get rid of the warts and all.

The company — which earlier this month decided to focus on its arsenal of kinase inhibitors — on Monday unveiled positive data from a pivotal study testing its lead experimental drug for use in common warts.

The drug, A-101, was tested in a 502-patient study called THWART-2 — patients enrolled had one to six warts before qualifying for the trial. Patients either self-administered A-101 topical solution or a vehicle twice a week over a two-month period. A higher proportion of patients on the drug (a potent hydrogen peroxide topical solution) saw their warts disappear at day 60, versus the vehicle (p<0.0001) — meeting the main goal of the study.  Each secondary endpoint also emerged in favor of A-101, the company said.

Charles Nichols, LSU School of Medicine

Could psy­che­delics tack­le the obe­si­ty cri­sis? A long­time re­searcher in the field says his lat­est mouse study sug­gests po­ten­tial

Psychedelics have experienced a renaissance in recent years amid a torrent of preclinical and clinical research suggesting it might provide a path to treat mood disorders conventional remedies have only scraped at. Now a preclinical trial from a young biotech suggests at least one psychedelic compound has effects beyond the mind, and — if you believe the still very, very early hype — could provide the first single remedy for some of the main complications of obesity.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare neu­ro­mus­cu­lar ail­ment

Acceleron is scrapping a muscular dystrophy development program underway for its number 2 drug in the pipeline after pouring over some failed mid-stage secondary data.

Gone is the ACE-083 project in patients with facioscapulohumeral muscular dystrophy. Their drug hit the primary endpoint on building muscle but flopped on key secondaries for functional improvements in patients, which execs felt was vital to the drug’s success.